Anna Sureda, MD, Ph.D., is the Head of the Clinical Hematology Department at the Catalan Institute of Oncology – L’Hospitalet de Llobregat in Barcelona, Spain, Associate Professor of Medicine at the University of Barcelona and leads a team of clinical hematologists, cancer researchers and other medical staff, with a focus on making real progress for patients living with cancer, including with CAR T-cell therapy. She is Co-Chair of the CAR T Vision Steering Committee, a clinical hematology investigator specializing in lymphomas and hematological malignancies as well as stem cell transplantation and cellular therapy strategies. Dr. Sureda is a regular reviewer of several peer-reviewed journals and has co-authored more than 500 manuscripts. Dr. Sureda reports honoraria from: Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche and Alexion. Dr. Sureda provides consultant support to Takeda, BMS/Celgene, Novartis, Janssen, Gilead and Sanofi. Dr. Sureda contributes as speaker's bureau for Takeda. Dr. Sureda has received institutional research support for clinical trials from Takeda and BMS/Celgene. Dr. Sureda is President of non-profit organisations GETH-TC and EBMT.

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types. Prof. Davies specialises in the treatment of malignant lymphoma. He has a particular interest in the investigation of monoclonal antibody-containing therapies and other novel therapeutics applied to lymphoma. His work also focuses on translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first in man lymphoma studies all the way through to leading late phase studies. He is Chair of the UK National Cancer Research Institute Lymphoma Research Groups and past Chair of the High Grade Lymphoma Study Group. He is Director of the Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults (TYA) and Clinical Lead for the Thames Valley and Wessex TYA Operational Delivery Network.

Dr. Mohamed Kharfan-Dabaja is a Professor of Medicine, vice-Chair of Hematology and Director of the Blood and Marrow Transplantation and Cellular Therapy Program at Mayo Clinic in Florida. He completed his fellowship in Hematology and Medical Oncology at The University of Miami, Jackson Memorial Hospital and Sylvester Comprehensive Cancer Center. His research focuses on CAR T-cell therapy in B-cell malignancies, hematopoietic cell transplantation, and evidence-based medicine research. He was the lead author of clinical practice recommendations on cellular immune therapies for treatment of chronic lymphocytic leukemia on behalf of the American Society for Transplantation and Cellular Therapy. He was the recipient of the 2025 King Hussein Lifetime Achievement Award for Cancer Research. He has more than 460 peer-reviewed publications and 24 book chapters.